Alexion Pharma GmbH
Alexion Pharma GmbH holds 21 Swissmedic orphan drug statuses in Switzerland, covering 14 rare diseases.
6 of its medicines are published with an authorisation number. Placing a medicine on the Swiss market requires an authorisation holder domiciled in Switzerland; the orphan drug status application does not, where a Swiss postal address suffices.
Medicines
- KanumaAuthorised
- KoselugoAuthorised
- SolirisAuthorised
- StrensiqAuthorised
- UltomirisAuthorised
- VoydeyaAuthorised
Orphan designations
Swissmedic publishes one row per medicine and orphan indication: the indication in the wording of the decision, the date the status was granted and, where the status was withdrawn, the withdrawal date. The table below reproduces those rows unchanged and links every indication to the matching rare disease in the directory.
| Orphan indication | Disease | Status granted | Status withdrawn |
|---|---|---|---|
| Behandlung der primären IgA Nephropathie | Primary IgA nephropathy | 25/08/2026 | Status active |
| Behandlung von Hypophosphatasie | Hypophosphatasia | 04/09/2025 | Status active |
| Behandlung der thrombotischen Mikroangiopathie nach hämatopoetischer Stammzelltransplantation (HSCT-TMA) | Conditioning before stem cell transplantation | 03/09/2025 | Status active |
| Behandlung von Myasthenia Gravis (MG) | Myasthenia gravis | 26/08/2025 | Status active |
| Behandlung von ATTR Amyloidose | Transthyretin amyloidosis (ATTR) | 15/04/2025 | Status active |
| Behandlung der paroxysmalen nächtlichen Hämoglobinurie | Paroxysmal nocturnal haemoglobinuria (PNH) | 01/06/2023 | Status active |
| Behandlung von Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) | Neuromyelitis optica spectrum disorder (NMOSD) | 27/02/2023 | Status active |
| Behandlung von Myasthenia Gravis (MG) | Myasthenia gravis | 22/06/2022 | Status active |
| Behandlung von Morbus Wilson | Wilson disease | 14/01/2022 | Status active |
| Behandlung von AL Amyloidose | AL amyloidosis (light-chain amyloidosis) | 11/01/2022 | Status active |
| Behandlung des atypischen hämolytisch-urämischen Syndroms (aHUS) | Atypical haemolytic uraemic syndrome (aHUS) | 13/07/2020 | Status active |
| Traitement de l'Hémoglobinurie paroxystique nocturne | Paroxysmal nocturnal haemoglobinuria (PNH) | 19/09/2019 | Status active |
| Behandlung von Erkrankungen des Neuromyelitis-Optica-Spektrums | Neuromyelitis optica spectrum disorder (NMOSD) | 13/09/2019 | Status active |
| Behandlung von Neurofibromatose Typ 1 (NF1) | Neurofibromatosis type 1 (NF1) | 08/03/2019 | Status active |
| Prévention du rejet de greffe aiguë suite à la transplantation d'organes solides | Transplant rejection after solid organ transplantation | 09/03/2017 | Status active |
| Myasthenia Gravis | Myasthenia gravis | 02/12/2016 | Status active |
| Behandlung der Mukopolysaccharidose Typ IIIB (Sanfilippo-B-Syndrom) | Mucopolysaccharidoses (MPS) | 29/03/2016 | Status active |
| Behandlung der Hypophosphatasie | Hypophosphatasia | 25/02/2013 | Status active |
| Wolman-Krankheit oder Cholesterinester-Speicherkrankheit (auf intrazellulärem Lipase-Mangel basierte Speicherkrankheit) | Wolman disease and cholesteryl ester storage disease | 02/07/2012 | Status active |
| Atypisches hämolytisch-urämisches Syndrom | Atypical haemolytic uraemic syndrome (aHUS) | 25/11/2011 | Status active |
| Behandlung der paroxysmalen nächtlichen Hämoglobinurie | Paroxysmal nocturnal haemoglobinuria (PNH) | 03/08/2007 | Status active |
Reimbursement
Whether this company's medicines are paid for by compulsory health insurance depends on the FOPH specialities list (SL), not on the orphan drug status. Medicines that are not listed can be reimbursed case by case under Art. 71a-71d KVV.
Frequently asked questions
How does a medicine obtain orphan drug status in Switzerland?
On application to Swissmedic. It requires a life-threatening or chronically debilitating disease affecting no more than 5 in 10,000 people in Switzerland, or an existing recognition in a country with comparable medicinal product control (Art. 4 para. 1 let. a decies TPA, Art. 4 TPLO).
What does the status actually give you?
The simplified authorisation procedure (Art. 14 para. 1 let. f TPA), priority assessment, a waiver of the flat-rate fee for the new authorisation application and, on request, 15 years of document protection (Art. 11b para. 4 TPA). There is no market exclusivity as in the EU.
How current is the data on Alexion Pharma GmbH?
Swissmedic publishes the list of medicinal products with orphan drug status under Art. 7 TPLO and updates it monthly. The date of the data set processed here is shown at the foot of every page.
Bring your orphan drug to Switzerland
You can enquire about orphan drug status, authorisation and reimbursement in Switzerland. Any specialist service and its scope are agreed separately with the external partner.
- Public Swissmedic data
- Four language versions